Ribociclib - Isotope Labelled Standards
References
FAQ's
References
- Besong, Gilbert; Brain, Christopher Thomas; Brooks, Clinton A.; Congreve, Miles Stuart; Dagostin, Claudio; He, Guo; Hou, Ying; Howard, Steven; Li, Yue; Lu, Yipin; et al, Pyrrolopyrimidine Compounds as CDK inhibitors, Novartis AG; Astex Therapeutics Ltd., Switzerland, EP2331547B1, July 30. 2014
- Bao, Xun; Wu, Jianmei; Sanai, Nader; Li, Jing, Determination of total and unbound ribociclib in human plasma and brain tumor tissues using liquid chromatography coupled with tandem mass spectrometry, Journal of Pharmaceutical and Biomedical Analysis, Volume: 166, Pages: 197-204, 2019
Frequently Asked Questions
How are Ribociclib impurities detected and analyzed?
Ribociclib impurities are detected and analyzed using analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry (MS).
Are there any specific Ribociclib impurities that are of particular concern?
There are specific Ribociclib impurities of particular concern due to their potential impact on patient safety.
What measures control and minimize the presence of Ribociclib impurities during its synthetic process?
Measures such as careful selection of starting materials, optimization of reaction conditions, and implementation of purification techniques help control and minimize the presence of Ribociclib impurities during its synthetic process.
What are the temperature conditions required to store Ribociclib impurities?
Ribociclib impurities should be stored at a controlled room temperature between 2-8°C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.